Illumina (ILMN) Profit Margin History
Historical gross, operating and net quarterly profit margin for Illumina (ILMN) over the last 10 years. The current net profit margin for Illumina as of December 15, 2017 is 30.34%.
|Medical||Medical - Biomedical and Genetics||$31.616B||$2.398B|
|Illumina, Inc. is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array.|